High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases

  • Authors:
    • Kenji Fujiyoshi
    • Gou Yamamoto
    • Akemi Takahashi
    • Yoshiko Arai
    • Mina Yamada
    • Miho Kakuta
    • Kensei Yamaguchi
    • Yoshito Akagi
    • Yoji Nishimura
    • Hirohiko Sakamoto
    • Kiwamu Akagi
  • View Affiliations

  • Published online on: December 15, 2016     https://doi.org/10.3892/or.2016.5323
  • Pages: 785-792
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Genetic testing is needed for the treatment of colorectal cancer (CRC), especially molecular-targeted therapy. The effects of anti-EGFR therapy and prognosis are affected by the presence of KRAS mutations. However, whether primary CRC or metastatic tissues are appropriate in the analysis is still unclear. In the present study, we assessed the concordance of KRAS/BRAF mutation status and microsatellite instability (MSI) in primary CRC and corresponding metastases. This study enrolled 457 patients with surgically resected primary and corresponding metastatic CRC (499 synchronous metastases and 57 metachronous metastases) and seven local recurrences, and KRAS/BRAF mutation and MSI status were analysed for these tumours. The concordance rates of KRAS mutation, BRAF mutation, wild-type, MSI-H and MSS between primary CRC and corresponding metastases were 93.9% (214/228), 100% (30/30), 99.3% (304/306), 87.5% (21/24) and 100% (137/137), respectively. These high concordance rates were not different between synchronous and metachronous metastases. In conclusion, a high concordance of KRAS/BRAF mutation status and MSI status was observed between primary CRC and corresponding metastases in this study. Either primary CRC or metastatic tissues can be used for testing KRAS/BRAF mutation status and MSI status.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 37 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto H, Sakamoto H, et al: High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 37: 785-792, 2017
APA
Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M. ... Akagi, K. (2017). High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncology Reports, 37, 785-792. https://doi.org/10.3892/or.2016.5323
MLA
Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., Akagi, K."High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases". Oncology Reports 37.2 (2017): 785-792.
Chicago
Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., Akagi, K."High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases". Oncology Reports 37, no. 2 (2017): 785-792. https://doi.org/10.3892/or.2016.5323